



Solagran Limited

Solagran Limited
ACN 002 592 396
98-106 Moray Street
Melbourne, 3205
Victoria
Australia
Tel 61 3 9820 2699
Fax 61 3 9820 3155

24 October 2014

ASX Announcement

Solagran announces the appointment of Dr Ian Nisbet as Non-Executive Director and prospective Chairman.

Melbourne, Australia 24 October 2014: Solagran Ltd (ASX: SLA) announces the appointment of Dr Ian Nisbet as a Non-Executive Director, effective immediately. Subject to the company's achievement of certain milestones, Dr Nisbet will assume Chairmanship of Solagran and current Chairman and Founder, Dr Vagif Soultanov, will become a Non-Executive Director.

"The Board of Solagran welcomes Dr Ian Nisbet as a Non-Executive Director," said SLA Chairman Dr Vagif Soultanov. "He has over 30 years of drug development, business development and general management experience in the local and international biotechnology sector and, importantly, has developed a strong understanding of Solagran's products and science. His experience, input and strong networks in the biotechnology, commercial and scientific communities will assist in the company's growth and success."

Dr Nisbet is a co-founder and partner in the biotechnology consulting company Afandin Pty Ltd and a co-founder and Executive Director of the oncology drug development company Senz Oncology Pty Ltd. He has previously been CEO and Managing Director of Xenome Ltd and Meditech Research Ltd and held senior management positions at Millennium Pharmaceuticals Inc, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian currently serves as Chairman of Verva Pharmaceuticals Ltd and vivoPharm Pty Ltd; and is a non-Executive Director of Velacor Pty Ltd, Cerulean Pharma Australia Pty Ltd and Tunitas Therapeutics Australia Pty Ltd. He also holds an appointment as Deputy Director (Commercialisation) at the Australian Institute of Bioengineering and Nanotechnology (AIBN) at the University of Queensland.

ENDS

About Solagran

Solagran Ltd is a Melbourne-based biotechnology company. It manufactures and markets a range of unique, efficacious and proprietary products sourced from different species of conifer trees, targeting the fast-growing natural healthcare and nutraceutical sectors. Solagran's competitive advantage in the sector is its long history of scientific excellence, academic credibility and proprietary manufacturing innovations. The company's products range from registered pharmaceuticals to supplements and complementary medicines. Solagran has products marketed in Australia, Russia, Malaysia and the UAE, and registered in Indonesia and Singapore, with current negotiations to expand into new territories.

Read more: www.solagran.com